



Media Release

Cordlife's South Korea Partner EDGC Receives CAP Accreditation For Its Proprietary NIPT Services

- EDGC's clinically-approved NIPT services, NICE[®], can detect up to 10 chromosomal abnormalities with over 99% accuracy without putting the expectant mother and foetus at risk.
- Accreditation from the College of American Pathologists represents a gold standard for lab management and processes.
- NICE[®] is marketed under Cordlife's brand Genscreen[®] in Indonesia and Philippines.

SINGAPORE, 21 August 2018 – Eone-Diagnomics Genome Center Co. Ltd. ("**EDGC**") has received accreditation from the College of American Pathologists ("**CAP**"), the global gold standard for laboratory management and processes. EDGC is a South Korean genetic analysis firm that partnered with Cordlife Group Limited ("**Cordlife**") last year to offer its proprietary non-invasive prenatal testing ("**NIPT**") in Indonesia and the Philippines.

CAP evaluates the accuracy, reliability and sustainability of clinical laboratory practices and accredits organisations only when the highest standards are met or surpassed. EDGC achieved such standards and was successfully granted the accreditation.

Based in Incheon and listed on the KOSDAQ, EDGC announced a collaboration with Cordlife in December last year to market its clinically-approved NICE[®] (Non-Invasive Chromosome Examination) in two Southeast Asian markets, Indonesia and the Philippines. NICE[®] NIPT is marketed under Genscreen[®], a brand of Cordlife, and can detect up to 10 chromosomal abnormalities with over 99% accuracy without putting the expectant mother and foetus at risk. The test can be done as early as week 10 of gestation.

Mr. Michael Weiss, Group CEO and Executive Director of Cordlife Group Limited stated, "As the market leader in stem cell banking in Indonesia and the Philippines, we continue to expand and upgrade quality diagnostic offerings to ensure our clients get an ever broadening array of best-in-class healthcare services. CAP accreditation for EDGC reaffirms our commitment to this goal."

Miss Heeyoung Na, Managing Director of Marketing of EDGC expressed, "CAP accreditation is a major milestone for EDGC which validates our relentless pursuit of best practices in medical research even as we continue to develop further on the products and services of the next-generation."

End

Cordlife Group Limited
1 Yishun Industrial Street 1 • A'Posh Bizhub • #06-01/09 • Singapore 768160
Phone (65) 6238 0808 • Fax (65) 6238 1108
Find Out More • info@cordlife.com • For Cordlife Parents • customercare@cordlife.com
Company Registration Number: 200102883E



Media & Investor Contact Information

WeR1 Consultants Pte Ltd

Tel: (65) 6737 4844

Frankie Ho – frankieho@wer1.net

Jordan Teo – jordanteo@wer1.net

About Cordlife Group Limited

(Bloomberg: **CLGL**; Reuters: **CORD.SI**)

Incorporated in 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”) is a consumer health company and one of the leading providers of cord blood as well as cord lining banking services in Asia. Cordlife has been listed on the mainboard of Singapore Exchange (SGX: P8A) since March 2012.

Cordlife owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, Philippines and Indonesia, Cordlife operates the largest¹ private cord blood banks. It is amongst the top three market leaders in India and Malaysia. By January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank in the country, HealthBaby Biotech (Hong Kong) Co., Limited. Through its majority owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam.

The Group's stem cell processing and storage facilities in Singapore, Hong Kong, India and the Philippines are accredited by AABB (formerly known as the American Association of Blood Banks), the organisation behind the world's gold standard for cord blood banking. In April 2018, Stemlife Berhad, as the pioneer and the largest cord blood bank in Malaysia, also achieved AABB accreditation. In addition, Cordlife Singapore is accredited by FACT-Netcord, another world-class accreditation body for cord blood banks globally, co-founded by American Society of Blood and Marrow Transplantation and the International Society of Cellular Therapy. This makes Cordlife Singapore one of just six cord blood banks in the world to be accredited by both AABB and FACT-Netcord simultaneously. The Group's majority-owned Hong Kong Screening Centre, HealthBaby and Cordlife India also attained accreditation from the College of American Pathologists (“CAP”) for meeting the highest industry standards for laboratory services. These quality achievements underpin the Group’s commitment to providing the highest service quality for clients.

Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services for the mother and child segment including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and other genetic screening services. For more information, visit <http://cordlife.listedcompany.com>.

¹ Source : Deloitte & Touche Financial Advisory Services Limited report, 10 April 2013